期刊
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
卷 7, 期 4, 页码 115-121出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1759720X15588514
关键词
belimumab; lupus treatment; systemic lupus erythematosus
类别
Belimumab (Benlysta (R)) is a fully humanized monoclonal antibody that inhibits B-lymphocyte stimulator (also known as B cell activating factor of the tumor necrosis factor family) and was approved by the US Food and Drug Administration and the European Medicines Evaluation Agency for treatment of autoantibody-positive systemic lupus erythematosus (SLE) in adults. This review discusses the key findings of the phase III trials, post hoc analyses, and real-world postmarketing use of belimumab in the routine care of SLE patients. It also highlights the safety profile of belimumab and gives insight into its potential use to treat childhood-onset SLE. It concludes with a discussion of the current clinical trials investigating belimumab in specific SLE disease states and a look to the future with novel targeted B-cell therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据